Autopsy report · NCT05364944

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

“The recruitment was halted for strategic reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 7 months before it stopped.
• 19 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Debiopharm International SA

Sponsor type

Industry

Conditions

Acromegaly; GEP-NET

Interventions

Debio 4126; Sandostatin LAR; Somatuline ATG

Participants

19

Sites

14

Countries

Denmark, France, Germany, Israel, Italy, Poland, Spain, United Kingdom

Trials that died the same way

• High-intensity Exercise After Acute Cardiac Event (HITCARE)
  “Recruitment was stopped due to lack of funding.” (81% match in meaning)
• Focus on Fibre Study
  “There were issues with recruitment so study was stopped” (77% match in meaning)
• Early Administration of the Lutein/Zeaxanthin in Premature Newborns
  “Recruitment was not possible” (76% match in meaning)
• BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling
  “recruitment of subjects was halted prematurely. recruiting subjects halted prematurely” (75% match in meaning)
• Digital Prevention of Asthma
  “The recruitment stopped due insufficient funding.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.